Beam Therapeutics Inc

BEAM

$90.37

+322.6% (1 year change)

Market Cap

$5.96 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$18.76 - $138.52

The lowest and highst price in the last 52 weeks.

Price-Earnings Ratio

0.0x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Market Cap $5.96 Billion
Enterprise Value -
Dividend Yield $0.00 (0.0%)
1 Year Return +322.6%
52-Week High $138.52
52-Week Low $18.76
Beta 1.56
Outstanding Shares 62.6 Million
Avg 30 Day Volume 1.22 Million

Valuation

P/E Ratio 0.0
PEG -
Earnings per Share $0.00
Price to Sales Ratio -
Price to Book Ratio -
Revenue to Enterprise Value -
EBIT to Enterprise Value -
Total Debt to Enterprise Value -
Debt to Equity -

Profitability

Revenue -
Gross Profit -
EBIT -
Net Income -
Profit Margin -
Quarterly Earnings Growth (YoY) -
Return on Equity -
Return on Assets -
Return on Invested Capital -

News

Were Hedge Funds Right About Beam Therapeutics Inc. (BEAM)?

Were Hedge Funds Right About Beam Therapeutics Inc. (BEAM)?

No summary available.

Insider Monkey Insider Monkey, 3 days ago
Beam Therapeutics Inc (BEAM) CEO John M. Evans Sold $2.7 million of Shares

Beam Therapeutics Inc (BEAM) CEO John M. Evans Sold $2.7 million of Shares

Related Stocks: BEAM ,

GuruFocus GuruFocus, 22 days ago
Beam Therapeutics to Participate in the 2021 William Blair Biotech Focus Conference

Beam Therapeutics to Participate in the 2021 William Blair Biotech Focus Conference

CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that ...

Intrado Digital Media Intrado Digital Media, 23 days ago